A case of apolipoprotein E Toyonaka and homozygous apolipoprotein E2/2 showing non-immune membranous nephropathy-like glomerular lesions with foamy changes
暂无分享,去创建一个
A. Matsunaga | E. Muso | H. Yokoyama | Takao Saito | S. Hara | Y. Ushiogi | Tamayo Kato
[1] A. Matsunaga,et al. A case of nephrotic syndrome showing contemporary presence of apolipoprotein E2 homozygote glomerulopathy and membranous nephropathy-like findings modified by apolipoprotein E Toyonaka , 2018, Clinical nephrology. Case studies.
[2] A. Shimizu,et al. Membranous Nephropathy-Like Apolipoprotein E Deposition Disease with Apolipoprotein E Toyonaka (Ser197Cys) and a Homozygous Apolipoprotein E2/2 , 2018, Case Reports in Nephrology and Dialysis.
[3] T. Miyata,et al. A Case of Lipoprotein Glomerulopathy with apoE Chicago and apoE (Glu3Lys) Treated with Fenofibrate , 2017, Case Reports in Nephrology and Dialysis.
[4] Irina Florina Tudorache,et al. Apolipoprotein E - A Multifunctional Protein with Implications in Various Pathologies as a Result of Its Structural Features , 2017, Computational and structural biotechnology journal.
[5] H. Nakashima,et al. Topics in lipoprotein glomerulopathy: an overview , 2014, Clinical and Experimental Nephrology.
[6] T. Mochizuki,et al. Glomerulopathy with Homozygous Apolipoprotein E2: A Report of Three Cases and Review of the Literature , 2013, Case Reports in Nephrology and Dialysis.
[7] Tariq Ahmad Masoodi,et al. Screening and Evaluation of Deleterious SNPs in APOE Gene of Alzheimer's Disease , 2012, Neurology research international.
[8] M. Caslake,et al. Apolipoproteins: metabolic role and clinical biochemistry applications , 2011, Annals of clinical biochemistry.
[9] Jianglei Chen,et al. Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions , 2011, Proceedings of the National Academy of Sciences.
[10] Radiya M. Sojitrawala,et al. A monomeric, biologically active, full-length human apolipoprotein E. , 2007, Biochemistry.
[11] S. Oikawa,et al. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[12] K. Weisgraber,et al. Influence of apoE domain structure and polymorphism on the kinetics of phospholipid vesicle solubilization DOI 10.1194/jlr.M200157-JLR200 , 2002, Journal of Lipid Research.
[13] V. Narayanaswami,et al. Lipid association-induced N- and C-terminal domain reorganization in human apolipoprotein E3. , 2001, The Journal of biological chemistry.
[14] I. Sakata,et al. Novel glomerular lipoprotein deposits associated with apolipoprotein E2 homozygosity. , 2001, Kidney international.
[15] T. Kita,et al. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. , 1999, Kidney international.
[16] J. Sasaki,et al. Apolipoprotein E Sendai (arginine 145-->proline): a new variant associated with lipoprotein glomerulopathy. , 1997, Journal of the American Society of Nephrology : JASN.
[17] R. Mahley,et al. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.